Mavacamten for mid-to-apical obstruction in HCM
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hypertrophic cardiomyopathy, with a thickened heart wall (≥15 mm on an echo or MRI, or ≥13 mm with a known genetic cause).
- You have symptoms like chest pain, shortness of breath, dizziness, or fainting, and are in NYHA class II or III (meaning symptoms with moderate activity).
- You have a pressure gradient over 30 mmHg in the mid-ventricle or apex of the heart at rest or when bearing down (Valsalva).
- You do not have obstruction in the usual outflow tract (gradient must be under 30 mmHg at rest and with Valsalva in that area).
- Your heart pumping strength is normal (LVEF at least 50%).
- You do not have other serious heart problems, uncontrolled high blood pressure, or conditions like Fabry disease or amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This study looks at how a drug called mavacamten, which relaxes the heart muscle, works in people with obstructive hypertrophic cardiomyopathy. It uses genetic testing to try to predict who will respond best to the drug.
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.